This is my immediate focus. If the $2.65 options are in the money before December then I don't think we will need to worry about the $1.25 options in May.
More seriously, on a macro scale just about everything that could go wrong in the small biotech space has gone wrong. Companies release great data and their SP falls. Huge numbers of US biotechs are trading on negative equity and the specialist investors in the USA there are giving up and going home. We have a trade war between China and the USA and a real war in the Middle East. Inflation is sticky worldwide with no sign interest rates are coming down anytime soon. To top it all off we have turmoil at the FDA and a capricious leader wanting to throw the baby out with the bathwater. All of this will pass in time, but it is trying.
I am very glad we have taken a cautious approach to capital management. We are funded past the end of 2026 and could probably make our cash last longer of we really needed to. Life wasn't meant to be easy I guess
(20min delay)